Mor Adam, Bingham Clifton O, Barisoni Laura, Lydon Eileen, Belmont H Michael
Division of Rheumatology, Department of Medicine, New York University School of Medicine/Hospital for Joint Diseases, New York, New York, USA.
J Rheumatol. 2005 Apr;32(4):740-3.
Tumor necrosis factor-alpha (TNF-alpha) is a proinflammatory cytokine. Agents that neutralize TNF-alpha are effective in the treatment of disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), spondyloarthropathies, and inflammatory bowel disease. TNF-alpha antagonist therapy has been associated with the development of antinuclear antibodies (ANA) and double-stranded DNA (dsDNA) antibodies, as well as the infrequent development of systemic lupus erythematosus (SLE)-like disease. We describe the first case of biopsy-confirmed proliferative lupus nephritis and leukocytoclastic vasculitis in a patient treated with etanercept for JRA.
肿瘤坏死因子-α（TNF-α）是一种促炎细胞因子。中和TNF-α的药物在治疗类风湿性关节炎、青少年类风湿性关节炎（JRA）、脊柱关节病和炎症性肠病等疾病方面有效。TNF-α拮抗剂治疗与抗核抗体（ANA）和双链DNA（dsDNA）抗体的产生有关，也与罕见的系统性红斑狼疮（SLE）样疾病的发生有关。我们描述了第一例经活检证实为增殖性狼疮性肾炎和白细胞破碎性血管炎的病例，该患者因JRA接受了依那西普治疗。
